Subscribe
1heals
1heals / iStockphoto.com
29 November 2017Big Pharma

Life sciences industry calls for Brexit transition period

The EU and UK must make progress in Brexit negotiations “as soon as possible”, according to the associations that represent the European and British life sciences industry.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
After Brexit: new directions for clinical trials
10 October 2017   If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.
Big Pharma
Big pharma companies react to ‘Brexit’
28 June 2016   Following the result of the UK’s referendum on membership of the EU, pharmaceutical companies have yet to find out how this will affect their businesses.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Big Pharma
After Brexit: new directions for clinical trials
10 October 2017   If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.
Big Pharma
Big pharma companies react to ‘Brexit’
28 June 2016   Following the result of the UK’s referendum on membership of the EU, pharmaceutical companies have yet to find out how this will affect their businesses.

More on this story

Big Pharma
After Brexit: new directions for clinical trials
10 October 2017   If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.
Big Pharma
Big pharma companies react to ‘Brexit’
28 June 2016   Following the result of the UK’s referendum on membership of the EU, pharmaceutical companies have yet to find out how this will affect their businesses.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler